Urolog. pro Praxi, 2005; 4: 159-163
CONSEQUENCE OF HORMONE REPLACEMENT THERAPY IN UROLOGY AND TRENDS OF NEXT RESEARCH
- Porodnická a gynekologická klinika, LF UK a FN v Hradci Králové
At around the menopause detriorating ovarian function leads to symptoms of estrogen deficiency syndrome and increased incidence of urinary symptoms including dysuria, fequency, nocturia, urgency and incontinence as well as the development of recurrent urinary tract infections. These symptoms are common and distressing and may be the result of estrogen deficiency or a manifestation of the aging process. Estrogens may improve urogenital complaints, but use of estrogen therapy for the treatment of urinary incontinence remains controversial. Estrogen replacement appears to alleviate the symtoms of urgency, urge incontinence, frequency, nocturia and dysuria and low-dose estradiol therapy is effective in manegement of atrophic vaginitis. Recurrent urinary tract infections my be prevent by estrogen therapy. New ways for the next research should be found in new kinds of estrogen administration and in lowering the estradiol doses. In recent meta-analyses was found lowe-dose vaginal estradiol to be as effective as systemic therapy for the treatment of urogenital atrophy.
Keywords: Key words: menopause, estrogen-deficiency syndrome, urogenital symptoms, hormone replacement therapy, vaginal estrogen administration.
Published: January 1, 2006 Show citation
References
- Buchsbaum GM, Duecy E, Kerr LA. Why women delay seeking treatment for urinary incontinence. 15th Annual Meeting, Washington, D. C., October 6-9, 2004: NAMS, abstract book, 94.
- Cronje WH, Studd J. Vaginal estrogens: is there a role for their use? The management of the menopause. Third eddition. Ed by John Studd, Parthenon Publishing, New York, London, 2003: 213-220.
- Crosignani P, Hendrix S, Pinn V. Chapter 10: Gynecologic and urinary aspects of menopause. In international position paper on women´s health and menopause: A coprehensive approach. U. S. Department of Health and Human Services 2002: 203-216.
Go to original source... - Donát J. Efficacy of and tolerance towards different kinds of hormone replacement therapy. The management of the menopause. Third eddition. Ed by John Studd, Parthenon Publishing, New York, London, 2003: 199-211.
- Donát J. Hormonální substituční terapie. Hradec Králové: Domena, 1999: 191.
- Donát J. Postmenopauza - estrogenní deficit v klinické praxi. Praha: Domena, 2003: 184.
- Hammar M, Christau S, Nathorst-Boss J, Rud T, Garre K. A double-blind randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br. J. Obstet. Gynaecol., 1998; 105: 904-911. Go to original source...
Go to PubMed... - Chen YCh, Chen GD, Hu SW, et al. Is the occurrence of storage and voiding dysfunction affected by menopausal transition or associated with the normal aging process? Menopause, 2003; 10: 203-208. Go to original source... Go to PubMed...
- Morris EP, Wilson POG, Robinson J, Rymer JM. Long-term effects of tibolone on the genital tract in postmenopausal women. Br. J. Obstet. Gynaecol., 1999; 106: 954-959. Go to original source... Go to PubMed...
- Robinson D, Cardozo L. Urogenital atrophy. In: The management of the menopause. Third eddition. Ed John Studd. The Parthenon Publishing Group. New York, London, 2003: 41-49.
- Santen RJ, Pinkerton JoAnn V, Conaway M, et al. Treatment of urogenital atrophy with low-dose estradiol: preliminary results. Menopause, 2002; 9: 179-187. Go to original source... Go to PubMed...
- Wakamatsu MM. What affects bladder function more: Menopause or age? Menopause, 2003; 10: 191-192. Go to original source... Go to PubMed...
- 15th NAMS Annual Meeting, Washington, D. C., October 6-9, 2004, Symposium 5: Achieving postmenopausal urogenital health. 2004 The North American Menopause Society.